Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) [rubitecan] Versus Gemcitabine HCl in Chemonaive Pancreatic Cancer Patients.

Trial Profile

Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) [rubitecan] Versus Gemcitabine HCl in Chemonaive Pancreatic Cancer Patients.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2011

At a glance

  • Drugs Gemcitabine; Rubitecan
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Dec 2011 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently' (last verified June 2007).
    • 15 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top